AI
Tuesday, January 14, 2025 1:47:03 PM
That’s actually a valid question since many are unaware of the “nature” of this deal…
The “nature” was publicly announced: The nature of the deal is that NWBO licensed another novel patent-fortified dendritic cell platform technology from Roswell that provides NWBO with the rights to produce and commercialize the drug (if the platform continues in clinical development to reach regulatory approval). The Roswell deal mirrors the commercial rights that NWBO owns with regard to the UCLA technology (DCVax-L)…
Currently, both novel platform technologies owned by NWBO are in combo trials at UCLA and at Roswell Park. The combo trials include Merck’s pembrolizumab, the studies have progressed beyond the initial stages of PII, interim efficacy data are beginning to emerge, and the three combo studies are supported by continuing peer-reviewed grants awarded by the U.S. NIH and the U.S. DoD.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175662581
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
